Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)

Market Cap	3.45B -12.1%
Revenue (ttm)	1.40B +9.2%
Net Income	154.99M +10.5%
EPS	1.14 +9.6%
Shares Out	135.44M
PE Ratio	22.37
Forward PE	n/a
Dividend	0.60 (2.34%)
Ex-Dividend Date	Jun 5, 2026

Volume	640,500
Open	25.38
Previous Close	25.50
Day's Range	24.81 - 25.50
52-Week Range	21.90 - 30.80
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 22, 2026

About SHA:603351

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3350 API/polyethylene glycol 4000 API. It also provides biomaterial products; water-ethylene glycol fire resistant hydraulic fluid, biodegradable hydrau...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603351

Financial Performance

In 2025, SHA:603351's revenue was 1.34 billion, an increase of 2.95% compared to the previous year's 1.30 billion. Earnings were 150.97 million, an increase of 3.11%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error